DR info

臨床試験数 : 31 / 薬物数 : 44 - (DrugBank : 18) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 101

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Anti-thymocyte globulin
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Autologous Peripheral Blood Stem Cell Transplantation
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Azathioprine
   Hospices Civils de Lyon
      1996   Phase 4   NCT00399399   Switzerland;
Benralizumab
   ASTRAZENECA AB
      2020   Phase 3   EUCTR2019-001832-77-IT   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-001832-77-DE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001832-77-GB   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001832-77-FR   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
Corticosteroid and azathioprine
   Assistance Publique - Hôpitaux de Paris
      2008   Phase 3   NCT00647166   France;
Cyclophosphamide
   Assistance Publique - Hôpitaux de Paris
      2016   Phase 3   NCT02807103   France;
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
   Hospices Civils de Lyon
      1996   Phase 4   NCT00399399   Switzerland;
   University of Parma
      2008   Phase 2   NCT00751517   Italy;
Cyclophosphamide, Azathioprine,prednisone,methylprednisolone
   Assistance Publique - Hôpitaux de Paris
      2005   Phase 4   NCT00307671   France;
Cyclosporine
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Fasenra
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-001832-77-DE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
Filgrastim
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Freeze-Dried Sulfonated Human Normal Immunoglobulin (GGS)
   TEIJIN PHARMA LIMITED
      2006   Phase 3   JPRN-JapicCTI-060242   -
HPC cell infusion
   Mounzer Agha
      2016   Early Phase 1   NCT02728271   -
Hydroxychloroquine
   Guy's and St Thomas' NHS Foundation Trust
      2020   Phase 4   NCT04316494   United Kingdom;
Infliximab
   Assistance Publique - Hôpitaux de Paris
      2004   -   NCT00307593   France;
L04AC06
   ASTRAZENECA AB
      2020   Phase 3   EUCTR2019-001832-77-IT   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-001832-77-DE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001832-77-GB   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001832-77-FR   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
MEDI-563
   ASTRAZENECA AB
      2020   Phase 3   EUCTR2019-001832-77-IT   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-001832-77-DE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001832-77-GB   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001832-77-FR   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
Mepolizumab
   ASTRAZENECA AB
      2020   Phase 3   EUCTR2019-001832-77-IT   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-001832-77-DE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001832-77-GB   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001832-77-FR   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
   Brigham and Women's Hospital
      2007   Phase 1/Phase 2   NCT00527566   United States;
   Children's Hospital Medical Center, Cincinnati
      2001   Phase 1/Phase 2   NCT00266565   United States;
   GlaxoSmithKline
      2015   Phase 3   NCT03298061   Belgium;Canada;France;Germany;Japan;United Kingdom;United States;
      2014   Phase 3   NCT02020889   Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
   University Hospital of Schleswig-Holstein (UKSH), Campus Lübeck
      2008   -   EUCTR2006-001791-20-DE   Germany;
   University of Schleswig-Holstein
      2008   Phase 2   NCT00716651   Germany;
Methotrexate
   University of Parma
      2008   Phase 2   NCT00751517   Italy;
Methylprednisolone
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Mycophenolate mofetil,methotrexate
   Assistance Publique - Hôpitaux de Paris
      2005   Phase 4   NCT00307671   France;
Naltrexone Hydrochloride
   University of Pennsylvania
      2019   Phase 2   NCT03482479   United States;
Nucala
   GlaxoSmithKline
      2018   -   NCT03557060   Japan;
Nucala 100 mg powder for solution for injection
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-001832-77-DE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
Placebo (physiological saline)
   TEIJIN PHARMA LIMITED
      2006   Phase 3   JPRN-JapicCTI-060242   -
Plaquenil - Hydroxychloroquine 200mg Film coated tablets
   Guy's and St. Thomas' NHS Foundation Trust
      2020   Phase 4   EUCTR2018-001268-40-GB   United Kingdom;
Prednisolone
   GlaxoSmithKline
      2015   Phase 3   NCT03298061   Belgium;Canada;France;Germany;Japan;United Kingdom;United States;
Prednisone
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
   Fernando Fervenza
      2007   Phase 2   NCT00424749   United States;
Prednisone, methylprednisolone,cyclophosphamides
   Assistance Publique - Hôpitaux de Paris
      2005   Phase 4   NCT00307671   France;
Rituximab
   Assistance Publique - Hôpitaux de Paris
      2016   Phase 3   NCT02807103   France;
      2004   -   NCT00307593   France;
   Fernando Fervenza
      2007   Phase 2   NCT00424749   United States;
SB-240563
   University Hospital of Schleswig-Holstein (UKSH), Campus Lübeck
      2008   -   EUCTR2006-001791-20-DE   Germany;
SB-240563 (mepolizumab)
   GlaxoSmithKline Research Ltd
      2015   Phase 3   EUCTR2014-003162-25-GB   Belgium;Canada;France;Germany;Japan;United Kingdom;
      2015   Phase 3   EUCTR2014-003162-25-DE   Belgium;Canada;France;Germany;Japan;United Kingdom;
      2015   Phase 3   EUCTR2014-003162-25-BE   Belgium;Canada;Germany;Japan;United Kingdom;United States;